- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01850186
Comparative Study of Dual Yellow Laser Versus Stabilized Kilnman Preparation in the Treatment of Melasma
Recent data highlight the role of vascularity in melasma and a recent study showed the interest to target this vascular component by pulsed dye laser. The Dual Yellow laser is a copper bromide laser emitting dual wavelength (green 511nm and yellow 578 nm). This laser can target both the vascular and pigmented components of melasma. A preliminary study has shown its efficacy and excellent tolerability in the treatment of melasma. This study requires however to be confirmed by a comparative study versus reference treatment.
Main objective To compare the efficacy on melasma at 6 month post treatment of a Dual Yellow Laser preceded by 1 month of kilnman trio and the kilnman trio monotherapy for 3 months in an intra-patient study.
Secondary objectives
- To study the frequency of PPI.
- Compare the rate and extent of recurrence 6 months after completion of treatment.
- To study the occurrence of possible adverse effects.
- Compare the effectiveness of Dual Yellow laser to kilnman trio monotherapy at S12 (end of treatment).
- To study patient satisfaction on the effectiveness and tolerability of the study treatments.
Methods Monocentric prospective interventional randomized split face comparative study between experimental treatment versus reference treatment.
Intervention
- Visit Selection Patients will be selected from those presenting to the consultation of the department of dermatology at University Hospital of Nice. Participation will be offered to patients corresponding to the selection criteria of the study.
Visit V0: Inclusion and early treatment After a minimum of 15 days, patients will begin the study. This will ensure that patients signed informed consent. An initial clinical evaluation of melasma with calculation of MASI score and standardized photographs (see chapter 'assessment') will be made. An examination by confocal microscopy in vivo will be realized. All patients will receive treatment by stabilized kilnman trio for four weeks.
In the week prior to Visit 1, the side of the face to receive the laser treatment will be determined by randomisation.
Visit V1: (Week 4) Clinical evaluation of melasma with calculation of MASI score and photographs will be made. Possible side effects (including PPI) will be noted.
The next trio will be treated with depigmenting kilnman trio for another 8 weeks. The contralateral side will receive its first laser session. Given the results of analysis by intention to treat, the occurrence of serious side effects will result in discontinuation of treatment but monitoring will continue with the assessments.
Visit V2: (week 6) Clinical evaluation of melasma with calculation of MASI score and photographs will be made. Possible side effects (including PPI) will be noted.
The laser side will receive its second session. Patients continue the applications of cream on the contralateral side.
Visit V3 (week 9) Clinical evaluation of melasma with calculation of MASI score and photographs will be made. Possible side effects (including PPI) will be noted.
The laser side will receive its third session.Patients continue the applications of cream on the contralateral side.
Visit V4 (week 12) Clinical evaluation of melasma with calculation of MASI score and photographs will be made. Possible side effects (including PPI) will be noted.
The laser side will receive its fourth and final session. Patients continue the applications of cream on the contralateral side during 4 weeks.
- Visit V5: (week 18) Clinical evaluation of melasma with calculation of MASI score and photographs will be made. Possible side effects (including PPI) will be noted. An assessment by in vivo confocal laser will be realized.
- Visit V6: (week 24) Clinical evaluation of melasma with calculation of MASI score and photographs will be made. Possible side effects (including PPI) will be noted. An assessment by in vivo confocal laser will be realized.
- Visit V7 (final week 36):
Clinical evaluation of melasma with calculation of MASI score and photographs will be made. Possible side effects (including PPI) will be noted. An assessment by in vivo confocal laser will be realized. The evaluation of safety and patient satisfaction will be performed using a visual analog scale.
The primary endpoint will be the MASI score, score approved for assessment of melasma treatments.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Alpes-Maritimes
-
Nice, Alpes-Maritimes, France, 06
- CHU de Nice - Hôpital Archet
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Inclusion criteria
- Age ≥ 18 years, ≤75 years.
- Clinical diagnosis of melasma
- Fitzpatrick phototype 1 to 4.
- Effective contraception will be maintained for the duration of the study.
- Affiliation to the Social Security
- Informed consent signed by the patient
Exclusion Criteria:
- Pregnant or breastfeeding women; effective contraception will be maintained for the duration of the study.
- Fitzpatrick phototype ≥ 5
- Intolerance or allergy to compounds of
- Exposure to UV or concomitant exposure to the sun without 50+ protective shield.
- Concomitant topical treatments may be effective on melasma (topical corticosteroids, topical retinoids)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dual yellow Laser
Patients will receive treatment by stabilized kilnman trio for four weeks (one application per day).
Patient will receive 4 treatments by Dual yellow Laser on the hemi-face (side determinated by randomisation, split body study) at weeks 4, 6, 9 and 12.
|
Patients will receive treatment by stabilized kilnman trio for four weeks (one application per day).
Patient will receive 4 treatments by Dual yellow Laser on the hemi-face (side determinated by randomisation, split body study) at weeks 4, 6, 9 and 12.
|
Placebo Comparator: Stabilized kilnman trio
Patients will receive treatment by stabilized kilnman trio for four weeks on all the face (one application per day).
At the beginning of week 5, Patient will receive stabilized kilnman trio on the hemi-face during three months (side not treated by dual yellow laser, split body study).
The stabilized kilnman trio will be prescribed for one month at inclusion (applied all over the face), and on the half of the face not treated by laser at weeks 4, 8 and 12.
|
The stabilized kilnman trio will be prescribed for one month at inclusion (all over the face, one application per day), and on the half of the face not treated by laser at weeks 4, 8 and 12 (one application per day).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Scoring systems in dermatology
Time Frame: 36 weeks
|
The primary endpoint will be the Scoring systems in dermatology (MASI score), score approved for assessment of melasma treatments compared between inclusion and after 6 month of treatment. A blind treatment evaluation of direct light, UV and polarized photographs (VISIA, cornfield ©) between inclusion and after 6 month of treatment will be performed by an independent observer (dermatologist). |
36 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tolerance and sever adverse event
Time Frame: 36 weeks
|
|
36 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: PASSERON Thierry, PU-PH, CHU de Nice - Hôpital de l'Archet - Dermatology
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 11-PP-15
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Melasma
-
Mesoestetic Pharma Group S.L.Completed
-
ConBio, a Cynosure CompanyCompleted
-
University of Nove de JulhoRecruiting
-
Jinnah Postgraduate Medical CentreActive, not recruiting
-
China Medical University HospitalCompleted
-
VIST - Faculty of Applied SciencesActive, not recruiting
-
China Medical University HospitalApollo Medical Optics, LtdCompleted
-
Combined Military Hospital AbbottabadCompleted
-
Northwestern UniversityCompleted
-
Centre Hospitalier Universitaire de NiceCompleted
Clinical Trials on Dual yellow Laser
-
Manchester University NHS Foundation TrustTopcon Corporation; Optos, PLCWithdrawnDiabetic Macular OedemaUnited Kingdom
-
Tampere University HospitalTampere University of TechnologyCompletedRosacea | TelangiectasiaFinland
-
Al-Azhar UniversityRecruiting
-
Cairo UniversityCompletedDiabetic Retinopathy | Macula EdemaEgypt
-
University of California, IrvineBeckman Laser InstituteActive, not recruiting
-
University of MalayaUnknownDiabetic Macular EdemaMalaysia
-
Ospedale San RaffaeleCompletedAge-Related Macular Degeneration | Geographic Atrophy | Reticular PseudodrusenItaly
-
Al Hadi HospitalCompletedDiabetic Macular EdemaKuwait
-
Tokat Gaziosmanpasa UniversityCompletedMolar, Third | Low-level Laser TherapyTurkey
-
LUTRONIC CorporationCompleted